The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice

Nutritional Research and Fetal Programming: Parental Nutrition Influences the Structure and Function of the Organs

(2021) Marcia Barbosa Aguila et al.   INTERNATIONAL JOURNAL OF MORPHOLOGY

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Mammalian Target of Rapamycin‐Perilipin 3 (mTORC1‐Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis

(2021) Marina Garcia‐Macia et al.   HEPATOLOGY

Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist

(2021) Rayane Miranda Pontes-da-Silva et al.   INTERNATIONAL JOURNAL OF OBESITY

Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1

(2021) So Yeong Cheon et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide

(2021) Baptist Gallwitz et al.   Frontiers in Endocrinology

Pancreatic islet cells disarray, apoptosis, and proliferation in obese mice. The role of Semaglutide treatment

(2021) Thatiany de Souza Marinho et al.   BIOCHIMIE

Mice as an Animal Model for the Study of Adipose Tissue and Obesity

(2021) Carlos Alberto Mandarim-de-Lacerda et al.   INTERNATIONAL JOURNAL OF MORPHOLOGY

The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon

(2021) Renata Spezani et al.   LIFE SCIENCES

High ratio of ω-3/ω-6 polyunsaturated fatty acids targets mTORC1 to prevent high fat diet-induced metabolic syndrome and mitochondrial dysfunction in mice

(2020) Run Liu et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Semaglutide injection for the treatment of adults with type 2 diabetes

(2020) Richard A Chudleigh et al.   Expert Review of Clinical Pharmacology

The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research

(2020) Nathalie Percie du Sert et al.   EXPERIMENTAL PHYSIOLOGY

Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway

(2020) Na Ao et al.   PEPTIDES

Pathological Consequences of Hepatic mTORC1 Dysregulation

(2020) Chun-Seok Cho et al.   Genes

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

(2020) Mohammad S. Kuchay et al.   DIABETOLOGIA

Sestrin2 protects against bavachin induced ER stress through AMPK/mTORC1 signaling pathway in HepG2 cells

(2020) Ying Yang et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

(2019) Liping Zhang et al.   Journal of Parkinsons Disease

Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease

(2019) Joan Khoo et al.   LIVER INTERNATIONAL

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

(2019) Philip Newsome et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sterol 12α-Hydroxylase Aggravates Dyslipidemia by Activating the Ceramide/mTORC1/SREBP-1C Pathway via FGF21 and FGF15

(2019) Preeti Pathak et al.   GENE EXPRESSION

DOCK5 regulates energy balance and hepatic insulin sensitivity by targeting mTORC1 signaling

(2019) Yerui Lai et al.   EMBO REPORTS

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment

(2018) Lene Jensen et al.   DIABETES OBESITY & METABOLISM

Semaglutide once-weekly: improved efficacy with a new safety warning

(2018) Scott A. Coon et al.   Expert Review of Clinical Pharmacology

Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse

(2017) Richard G. Peterson et al.   PLoS One

Treatment of nonalcoholic fatty liver disease: role of AMPK

(2016) Brennan K. Smith et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response

(2014) Hongliang Li et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

A New Method for Quantitative Real-Time Polymerase Chain Reaction Data Analysis

(2013) Xiayu Rao et al.   JOURNAL OF COMPUTATIONAL BIOLOGY

Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways

(2011) Jessica L. Yecies et al.   Cell Metabolism

Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c

(2010) P. Ferré et al.   DIABETES OBESITY & METABOLISM

A Mouse Model of Metabolic Syndrome: Insulin Resistance, Fatty Liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 Mice Fed a High Fat Diet

(2010) Julio C. Fraulob et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION